Julia Klermund

发表

Telomeric RNA-DNA hybrids affect telomere-length dynamics and senescence

Bettina Balk, B. Luke, Sarah Luke-Glaser, 2013, Nature Structural &Molecular Biology.

High nutrient levels and TORC1 activity reduce cell viability following prolonged telomere dysfunction and cell cycle arrest.

B. Luke, Katharina Bender, Julia Klermund, 2014, Cell reports.

Quantitative Evaluation of Chromosomal Rearrangements in Primary Gene-Edited Human Stem Cells by Preclinical CAST-Seq

Melanie Boerries, Claudio Mussolino, Toni Cathomen, 2020, SSRN Electronic Journal.

Clinical genome editing to treat sickle cell disease—A brief update

T. Cathomen, Julia Klermund, Parinaz Zarghamian, 2023, Frontiers in Medicine.

A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition

T. Rausch, J. Korbel, A. Trumpp, 2015, Aging.

Validation and Long-Term Follow Up of CD33 Off-Targets Predicted In Vitro and In Silico Using Error-Corrected Sequencing in Rhesus Macaques

S. Tsai, T. Cathomen, I. Tunc, 2020, bioRxiv.

Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq.

M. Boerries, T. Cathomen, C. Mussolino, 2021, Cell stem cell.

Checkpoint adaptation in recombination-deficient cells drives aneuploidy and resistance to genotoxic agents.

A. Busch, Olga Vydzhak, B. Luke, 2020, DNA repair.

Checkpoint adaptation in repair-deficient cells drives aneuploidy and resistance to genotoxic agents

S. Grimm, A. Busch, Olga Vydzhak, 2018, bioRxiv.

Prediction and Validation of Hematopoietic Stem and Progenitor Cell Off-Target Editing in Transplanted Rhesus Macaques.

S. Tsai, T. Cathomen, I. Tunc, 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

A novel Cas9 fusion protein promotes targeted genome editing with reduced mutational burden in primary human cells

T. Cathomen, C. Mussolino, G. Andrieux, 2023, Nucleic acids research.

Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1

M. Boerries, A. Abad, Á. Vales, 2024, EMBO molecular medicine.